Business
Nuvalent Appoints Ron Squarer to Board of Directors
CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely
About this update from Nuvalent, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors.\n \n \n \n \n \n \n \n\"We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch preparation,\" said James Porter, Ph.D., Chief Executive Officer at Nuvalent. \"We look forward to leveraging his deep expertise as we advance toward the potential first approval and launch of zidesamtinib for TKI pre-treated ROS1-positive non-small cell lung cancer in 2026.\"Mr. Squarer brings more than 30 years of proven leadership in oncology drug development and commercialization to the Nuvalent Board. Most recently, he served as the Board Chair of Deciphera Pharmaceuticals, which was acquired by Ono Pharmaceuticals in 2024. He also served as the Chief Executive Officer of Array Biopharma, where he oversaw the research, development, and successful commercialization of several oncology treatments, as well as the 2019 acquisition of the company by Pfizer. Prior to Array, Mr. Squarer held positions of increasing responsibility with Hospira, a global pharmaceutical and medical device company. Earlier in his career, he served as Senior Vice President of Global Corporate and Business Development at Mayne Pharma and held leadership roles at Pfizer and SmithKline Beecham Pharmaceuticals in the U.S. and Europe.\"Nuvalent's demonstrated ability to combine elegant molecular design with disciplined development and a clear understanding of medical needs has resulted in a pipeline of novel kinase inhibitors with the potential to make a meaningful impact for patients,\" said Mr. Squarer. \"This is the type of innovation that continues to advance toward a future where oncogene-driven cancers may one day be managed as a chronic condition more often than as a life-threatening disease. It is a privilege to join the Board of Directors as the team prepares for the potential commercialization of its first medicine, and I look forward to partnering to...